Table 1.

Clinic-pathological features of the “unadjusted” cohort.

Characteristics		Denosumab	Zoledronic Acid	p value	SMD
n		618	246
Premenopausal State	No	460 (74.4 %)	194 (78.9 %)	0.2	0.105
	Yes	158 (25.6 %)	52 (21.1 %)
Age (mean ± SD)		60.1 ± 12.7	61.0 ± 12.0	0.328	0.073
PS	0	556 (90.0 %)	201 (81.7 %)	0.001	0.239
	1	62 (10.0 %)	45 (18.3 %)
Histology	Ductal	443 (71.7 %)	165 (67.1 %)	0.405	0.101
	Lobular	133 (21.5 %)	61 (24.8 %)
	Other	42 (6.8 %)	20 (8.1 %)
Ki67 (mean ± SD)		23.5 ± 14.8	21.4 ± 15.0	0.079	0.139
Grading	G1-G2	294 (64.5 %)	131 (66.8 %)	0.623	0.05
	G3	162 (35.5 %)	65 (33.2 %)
Estrogen Receptor (mean ± SD)		86.7 ± 15.2	86.8 ± 14.7	0.926	0.007
Progesterone Receptor (mean ± SD)		46.4 ± 36.6	48.0 ± 36.2	0.575	0.046
Metastatic at Diagnosis	No	353 (57.2 %)	134 (54.5 %)	0.511	0.055
	Yes	264 (42.8 %)	112 (45.5 %)
Adjuvant Chemotherapy	No	364 (60.0 %)	153 (63.0 %)	0.465	0.062
	Yes	243 (40.0 %)	90 (37.0 %)
Adjuvant Endocrine Therapy	No	227 (39.4 %)	93 (40.6 %)	0.815	0.025
	Yes	349 (60.6 %)	136 (59.4 %)
Months of Adjuvant Endocrine Therapy (mean ± SD)		46.6 ± 30.1	41.6 ± 30.8	0.092	0.166
Bone-only disease	No	305 (49.4 %)	84 (34.1 %)	<0.001	0.312
	Yes	313 (50.6 %)	162 (65.9 %)
CDK4/6 Inhibitor	Abemaciclib	86 (13.9 %)	37 (15.0 %)	0.096	0.166
	Palbociclib	338 (54.7 %)	150 (61.0 %)
	Ribociclib	194 (31.4 %)	59 (24.0 %)
Line of Treatment	First	507 (84.4 %)	171 (70.1 %)	<0.001	0.345
	Second	94 (15.6 %)	73 (29.9 %)
Setting	Endocrine Resistant	245 (39.6 %)	121 (49.2 %)	0.013	0.193
	Endocrine Sensitive	373 (60.4 %)	125 (50.8 %)
Endocrine Therapy	Aromatase Inhibitor	397 (64.2 %)	138 (56.1 %)	0.032	0.167
	Fulvestrant	221 (35.8 %)	108 (43.9 %)